Authors
Latest:
HPV and the Immune System in Head and Neck Cancers: Therapeutic ConsiderationsA review of the role of immune therapy in HPV-associated head and neck squamous cell carcinoma, along with the evidence and perspective behind differing therapeutic considerations.
Latest:
Chemotherapy Drug Shortages: It’s SolubleHoward S. Hochster, MD, reviews the potential solutions for the current chemotherapy drug shortages, and how this can be avoided in the future.
Latest:
MAIC Study Finds Similar Results With Linvoseltamab/Teclistamab in R/R Multiple MyelomaSimilar outcomes were noted when linvoseltamab and teclistamab were analyzed as treatments for patients with relapsed/refractory multiple myeloma.
Latest:
Defining PSA Nadir After Definitive Therapy in Prostate CancerBrian Helfand, MD, PhD, describes the ways in which the PSA nadir can be defined after definitive therapy and the implications of the definition used for patients with prostate cancer.
Latest:
Managing Prostate Cancer Surgical Patients during the COVID-19 Pandemic: A Brief Report of the Duke Cancer Institute’s Initial ExperienceExperts from the Duke Cancer Institute outline their current approach to stratifying surgical management of patients with prostate cancer.
Latest:
Immune-Related Adverse Events Involving Multiple Organ Sites in a Patient Treated With Nivolumab Plus IpilimumabExperts discuss the case of a 56-year-old white man who presents with multiple immune-related adverse events
Latest:
Association of Financial Conflicts of Interest With Academic Productivity Among Junior Faculty in Hematology and OncologyConflicts of interest for junior faculty members were evaluated at top cancer centers by Suneel D. Kamath, MD, et al. to determine how financial conflicts of interest correlated with measures of academic career productivity.
Latest:
Sotorasib Demonstrates Promising Antitumor Activity in Advanced NSCLCSotorasib showed promising antitumor activity in patients with non-small cell lung cancer that harbor the KRAS p.G12C mutation.
Latest:
FDA OKs Zanubrutinib to Treat Leukemia SubtypesPatients with chronic lymphocytic leukemia and small lymphocytic leukemia can now receive treatment with zanubrutinib following its approval by the FDA.
Latest:
Mirvetuximab Yields HRQOL Improvement in FRα-Positive Ovarian CancerPatient reported outcomes from the phase 3 MIRASOL trial showed improvement when mirvetuximab was used vs standard of care in folate receptor-alpha positive ovarian cancer resistant ovarian cancer.
Latest:
Stephen Schuster, MD, Gives Advice for Treating Aggressive Lymphomas During COVID-19 PandemicStephen Schuster, MD, talked about the benefits of conducting routine visits remotely during the COVID-19 pandemic, allowing doctors to see and treat more patients safely and efficiently.
Latest:
Greater Sleep Disturbance Associated With External Factors in Patients With GI CancersIn patients with gastrointestinal cancers, factors such as younger age and comorbidities, among others, were significantly associated with a greater likelihood of sleep disturbance.
Latest:
Circulating KIM-1 May Predict Benefit With Atezolizumab in RCCKIM-1 was the most significantly enriched circulating protein in recurrence vs baseline serum samples among patients in the IMmotion010 trial.
Latest:
Eric Jonasch, MD, on Next Steps in MK-6482 in VHL Disease–Associated RCCThe MD Anderson Cancer Center expert discussed next steps for those with von Hippel-Lindau disease–associated renal cell carcinoma being treated with the HIF-2a Inhibitor.
Latest:
Amir Goldkorn, MD Talks Next Steps for SWOG 1216 TrialThe University of Southern California expert discusses next steps for the trial and how the recent results could impact the future of care for patients with prostate cancer.
Latest:
Courtney DiNardo, MD, on Looking Forward in AML TreatmentThe MD Anderson Cancer Center expert discussed the future of acute myeloid leukemia treatment, and how the field is evolving rapidly.
Latest:
Kelly Morgan, MS, CGC, the Future of Telemedicine and Genetic TestingThe MSK expert discussed how telemedicine may change genetic testing and its access for patients.
Latest:
Matthew Steven Davids, MD, MMSc, on the Venetoclax, R-EPOCH Combo for Richter’s SyndromeThe CLL expert spoke about the implications of this study for patients and how patients can apply this knowledge to their own course of treatment.
Latest:
Thierry André, MD, on Interim Results from the Phase III Keynote-177 StudyThe findings, presented at the 2020 ASCO Virtual Scientific Program, are the first to show benefit with pembrolizumab in patients with advanced colorectal cancer when used as a front-line therapy.
Latest:
Benoit You, MD, PhD, on the use of Avelumab to Treat Patients With Gestational Trophoblastic TumorsThe expert from the Centre Hospitalier Lyon-Sud discussed the results of a phase II study of avelumab for patients with GTT who were resistant to chemotherapy.
Latest:
John Kuruvilla, MD, Discusses Toxicities Observed in the Phase 3 KEYNOTE-204 StudyThe expert in hematology highlighted the toxicities reported in this trial and explained the differences observed between the 2 drugs studied.
Latest:
Dosing Lenvatinib for Treatment of Advanced Renal Cell CarcinomaKidney cancer experts explain how they dose lenvatinib in advanced renal cell carcinoma treatment to mitigate toxicities.
Latest:
Sacituzumab Govitecan Yields Improved Survival Regardless of Trop-2 Levels for HR+/HER2– Breast CancerImprovements in survival were observed in patients with pretreated, endocrine-resistant hormone receptor–positive, HER2-negative metastatic breast cancer who were treated with sacituzumab govitecan vs physician’s choice.
Latest:
Andres Poveda, MD, on the Implications of the Phase 3 SOLO2/ENGOT-ov21 TrialThe expert in ovarian cancer indicated that treatment with the studied maintenance olaparib tablets could aid patients in having a more regular lifestyle.
Latest:
Ponatinib-Related Toxicity Management in ALL/CML Improves Over TimeFrom 2013 to 2022, the rate of important identified risks associated with ponatinib in the treatment of those with ALL or CML had decreased.
Latest:
Atezolizumab with Neoadjuvant Chemo Does Not Meet End Points in TNBCAtezolizumab with chemotherapy did not yield a significant increase to event-free survival compared with placebo with chemotherapy, 85.2% vs 81.9%, respectively.
Latest:
Selinexor Combo Shows Activity in Myelofibrosis Spleen Responses, SymptomsMore than 80% of the SENTRY trial population had alleviation of their myelofibrosis-associated symptoms following treatment with selinexor/ruxolitinib.
Latest:
ASCO Expert on the Possible Benchmark Analysis of Autologous Transplantation in B-Cell LymphomasNirav Niranjan Shah, MD, discussed the analysis of autologous transplantation use in patients with relapsed, chemosensitive DLBCL and how it may become a comparator for other clinical trials.
Latest:
Cross Q&A: The Memorial Sloan-Kettering MavericksThe Moffitt Marrowvingians take their turn questioning the Memorial Sloan Kettering Mavericks on their presented clinical trial data.
